(Q24241813)

inferred from title

metastatic colon cancer

1 reference

1 reference

4

0 references

Susanne Unverzagt

5

0 references

author name string

Anna Dorothea ADW Wagner

1

0 references

Dirk Arnold

2

0 references

Axel AG Grothey

Cochrane Database of Systematic Reviews

3

0 references

publication date

8 July 2009

0 references

published in

0 references

cites work

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Antiangiogenic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

The implications of angiogenesis for the biology and therapy of cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Anti-angiogenic therapy: rationale, challenges and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Thirty years of Medical Research Council randomized trials in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Incidence and patterns of recurrence following curative resection for colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Estimating the world cancer burden: Globocan 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Modulating angiogenesis: more vs less

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathway—A Report of the Tumour Angiogenesis Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

7 January 2021

Update on clinical trials targeting vascular endothelial growth factor in cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

7 January 2021

When does the presence of the target predict response to the targeted agent?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

7 January 2021

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005392.PUB3

7 January 2021

10.1002/14651858.CD005392.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_uf67ue2su5cj7czaacbgrnwhqm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uf67ue2su5cj7czaacbgrnwhqm

24 November 2022

mapped directly with Wikidata item

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

19588372

1 reference

Consolidated OpenCitations Corpus – April 2017